NEPHROS, INC.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $18.8M | $14.2M | $14.2M | $10.0M | $10.2M | $8.6M | $10.3M | $5.7M |
| Cost of Revenue | $7.2M | $5.4M | $5.8M | $5.2M | $4.6M | $3.6M | $4.3M | $2.5M |
| Gross Profit | $11.6M | $8.7M | $8.4M | $4.7M | $5.6M | $4.9M | $6.1M | $3.2M |
| Gross Margin | 61.9% | 61.6% | 59.0% | 47.4% | 55.1% | 57.4% | 58.9% | 56.3% |
| Operating Expenses | ||||||||
| Research & Development | $1.3M | $906.0K | $873.0K | $1.3M | $1.5M | $2.8M | $3.1M | $1.5M |
| SG&A Expense | $9.0M | $7.7M | $8.9M | $7.6M | $7.2M | $6.5M | $6.1M | $4.5M |
| Operating Income | $1.1M | $6.0K | $-1.6M | $-4.3M | $-3.3M | $-4.3M | $-3.2M | $-3.0M |
| Operating Margin | 6.1% | 0.0% | -11.2% | -43.5% | -31.8% | -49.9% | -30.5% | -53.0% |
| Interest Expense | — | — | $2.0K | $20.0K | $41.0K | $110.0K | $195.0K | $172.0K |
| Pretax Income | $1.2M | $89.0K | $-1.6M | — | — | $-4.5M | $-3.4M | $-3.4M |
| Income Tax Expense | $12.0K | $15.0K | $0 | $0 | $0 | — | $-225.0K | $-93.0K |
| Net Income | $1.2M | $74.0K | $-1.6M | $-7.1M | $-3.9M | $-4.5M | $-3.2M | $-3.4M |
| Net Margin | 6.4% | 0.5% | -11.1% | -71.2% | -37.8% | -52.9% | -30.8% | -59.8% |
| EPS (Basic) | $0.11 | $0.01 | $-0.15 | $-0.73 | $-0.41 | $-0.52 | $-0.45 | $-0.50 |
| EPS (Diluted) | $0.11 | $0.01 | $-0.15 | $-0.73 | $-0.41 | $-0.52 | $-0.45 | $-0.50 |
| Shares Outstanding (Basic) | 10.6M | 10.5M | 10.4M | 10.3M | 10.0M | 9.9M | 8.1M | 7.2M |
| Shares Outstanding (Diluted) | 11.0M | 10.6M | 10.4M | 10.3M | 10.0M | 9.9M | 8.1M | 7.2M |
| Dividends Per Share | — | — | — | — | — | — | — | — |